M6A-modified circRBM33 promotes prostate cancer progression via PDHA1-mediated mitochondrial respiration regulation and presents a potential target for ARSI therapy
- PMID: 37056926
- PMCID: PMC10086746
- DOI: 10.7150/ijbs.77133
M6A-modified circRBM33 promotes prostate cancer progression via PDHA1-mediated mitochondrial respiration regulation and presents a potential target for ARSI therapy
Abstract
N6-Methyladenosine (m6A) is the most prevalent RNA modification in various types of RNA, including circular RNAs (circRNAs). Mounting evidence has shown that circRNAs may play critical roles in diverse malignancies. However, the biological relevance of m6A modification of circRNAs in prostate cancer (PCa) remains unclear and needs to be elucidated. Our data showed that circRBM33 was m6A-modified and was more highly expressed in PCa cells than in normal cells/tissues. The in vitro and in vivo experiments showed that downregulation/upregulation of circRBM33 inhibited/promoted tumour growth and invasion, respectively. Decreasing m6A levels rescued the tumour-promoting effect of circRBM33. Additionally, once modified by m6A, circRBM33 interacts with FMR1 by forming a binary complex that sustains the mRNA stability of PDHA1, a downstream target gene. Suppressed/overexpressed circRBM33 lowered/enhanced the ATP production, the acetyl-CoA levels and the NADH/NAD+ ratio. Moreover, depletion of circRBM33 significantly increased the response sensitivity to androgen receptor signalling inhibitor (ARSI) therapy, including enzalutamide and darolutamide, in prostate tumours. Our study suggested that the m6A-mediated circRBM33-FMR1 complex can activate mitochondrial metabolism by stabilizing PDHA1 mRNA, which promotes PCa progression, and can attenuate circRBM33 increased ARSI effectiveness in PCa treatment. This newly discovered circRNA may serve as a potential therapeutic target for PCa.
Keywords: ARSI therapy; N6-methyladenosine; Prostate cancer; circRBM33; mitochondrial respiration.
© The author(s).
Conflict of interest statement
Competing Interests: The authors have declared that no competing interest exists.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10086746/bin/ijbsv19p1543g001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10086746/bin/ijbsv19p1543g002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10086746/bin/ijbsv19p1543g003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10086746/bin/ijbsv19p1543g004.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10086746/bin/ijbsv19p1543g005.gif)
![Figure 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10086746/bin/ijbsv19p1543g006.gif)
![Figure 7](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10086746/bin/ijbsv19p1543g007.gif)
![Figure 8](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10086746/bin/ijbsv19p1543g008.gif)
![Figure 9](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10086746/bin/ijbsv19p1543g009.gif)
![Figure 10](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10086746/bin/ijbsv19p1543g010.gif)
Similar articles
-
Circular RNA RBM33 contributes to cervical cancer progression via modulation of the miR-758-3p/PUM2 axis.J Mol Histol. 2021 Apr;52(2):173-185. doi: 10.1007/s10735-020-09933-1. Epub 2021 Jan 5. J Mol Histol. 2021. PMID: 33398465
-
A prognostic signature consisting of N6-methyladenosine modified mRNAs demonstrates clinical potential in prediction of biochemical recurrence and guidance on precision therapy in prostate cancer.Transl Oncol. 2023 Jul;33:101670. doi: 10.1016/j.tranon.2023.101670. Epub 2023 Apr 13. Transl Oncol. 2023. PMID: 37060728 Free PMC article.
-
CircRBM33 regulates IL-6 to promote gastric cancer progression through targeting miR-149.Biomed Pharmacother. 2020 May;125:109876. doi: 10.1016/j.biopha.2020.109876. Epub 2020 Feb 7. Biomed Pharmacother. 2020. PMID: 32044717
-
Effect of circular RNAs and N6-methyladenosine (m6A) modification on cancer biology.Biomed Pharmacother. 2023 Mar;159:114260. doi: 10.1016/j.biopha.2023.114260. Epub 2023 Jan 17. Biomed Pharmacother. 2023. PMID: 36657303 Review.
-
The functional roles, cross-talk and clinical implications of m6A modification and circRNA in hepatocellular carcinoma.Int J Biol Sci. 2021 Jul 22;17(12):3059-3079. doi: 10.7150/ijbs.62767. eCollection 2021. Int J Biol Sci. 2021. PMID: 34421350 Free PMC article. Review.
Cited by
-
Role of N6‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review).Oncol Rep. 2024 Jun;51(6):88. doi: 10.3892/or.2024.8747. Epub 2024 May 17. Oncol Rep. 2024. PMID: 38757383 Free PMC article. Review.
-
Exome sequencing reveals genetic heterogeneity and clinically actionable findings in children with cerebral palsy.Nat Med. 2024 May;30(5):1395-1405. doi: 10.1038/s41591-024-02912-z. Epub 2024 May 1. Nat Med. 2024. PMID: 38693247
-
RNA m6a Methylation Regulator Expression in Castration-Resistant Prostate Cancer Progression and Its Genetic Associations.Cancers (Basel). 2024 Mar 27;16(7):1303. doi: 10.3390/cancers16071303. Cancers (Basel). 2024. PMID: 38610981 Free PMC article.
-
Advanced approaches of the use of circRNAs as a replacement for cancer therapy.Noncoding RNA Res. 2024 Mar 30;9(3):811-830. doi: 10.1016/j.ncrna.2024.03.012. eCollection 2024 Sep. Noncoding RNA Res. 2024. PMID: 38590433 Free PMC article. Review.
-
Non-coding RNA-Mediated N6-Methyladenosine (m6A) deposition: A pivotal regulator of cancer, impacting key signaling pathways in carcinogenesis and therapy response.Noncoding RNA Res. 2023 Nov 13;9(1):84-104. doi: 10.1016/j.ncrna.2023.11.005. eCollection 2024 Mar. Noncoding RNA Res. 2023. PMID: 38075202 Free PMC article. Review.
References
-
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. - PubMed
-
- Mottet N, van den Bergh R, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021;79(2):243–62. - PubMed
-
- Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M. et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol. 2021;79(2):263–82. - PubMed
-
- Rebello RJ, Oing C, Knudsen KE, Loeb S, Johnson DC, Reiter RE. et al. Prostate cancer. Nat Rev Dis Primers. 2021;7(1):9. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical